Anchor Investment Management LLC Raises Stock Position in AbbVie Inc. $ABBV

Anchor Investment Management LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 87,203 shares of the company’s stock after acquiring an additional 2,542 shares during the period. AbbVie comprises approximately 1.6% of Anchor Investment Management LLC’s investment portfolio, making the stock its 12th biggest holding. Anchor Investment Management LLC’s holdings in AbbVie were worth $19,925,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. TD Capital Management LLC raised its stake in AbbVie by 20.0% in the fourth quarter. TD Capital Management LLC now owns 822 shares of the company’s stock worth $188,000 after buying an additional 137 shares in the last quarter. BDFS Capital LLC bought a new stake in AbbVie during the 4th quarter valued at $203,000. Tempo Wealth LLC purchased a new position in shares of AbbVie in the 4th quarter valued at $627,000. KW Wealth Management LLC raised its position in shares of AbbVie by 10.0% in the 4th quarter. KW Wealth Management LLC now owns 4,573 shares of the company’s stock worth $1,045,000 after acquiring an additional 415 shares in the last quarter. Finally, MidFirst Bank bought a new position in shares of AbbVie in the 4th quarter worth $9,238,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.1%

AbbVie stock opened at $216.63 on Friday. The stock has a 50-day moving average price of $212.18 and a 200 day moving average price of $218.76. The company has a market capitalization of $382.74 billion, a price-to-earnings ratio of 106.71, a price-to-earnings-growth ratio of 0.66 and a beta of 0.32. AbbVie Inc. has a 52 week low of $181.73 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the prior year, the company earned $2.46 EPS. AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. Research analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ABBV shares. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a research report on Thursday, April 30th. Guggenheim reiterated a “buy” rating and set a $249.00 price objective on shares of AbbVie in a research note on Friday, May 1st. Finally, Morgan Stanley increased their target price on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $253.43.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
• Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
• Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.